Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 296

1.

Dietary Fiber, Whole Grains, and Head and Neck Cancer Prognosis: Findings from a Prospective Cohort Study.

Maino Vieytes CA, Mondul AM, Li Z, Zarins KR, Wolf GT, Rozek LS, Arthur AE.

Nutrients. 2019 Sep 27;11(10). pii: E2304. doi: 10.3390/nu11102304.

2.

Predictors and Prevalence of Nodal Disease in Salvage Oropharyngectomy.

Heft Neal ME, Brennan J, Brenner JC, Shuman AG, Chinn SB, Stucken CL, Malloy KM, Moyer JS, Casper KA, McLean SA, Prince MEP, Bradford CR, Wolf GT, Chepeha DB, Rosko AJ, Spector ME.

Ann Surg Oncol. 2019 Sep 19. doi: 10.1245/s10434-019-07841-7. [Epub ahead of print]

PMID:
31538289
3.

Prognostic Value of Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma.

Spector ME, Bellile E, Amlani L, Zarins K, Smith J, Brenner JC, Rozek L, Nguyen A, Thomas D, McHugh JB, Taylor JMG, Wolf GT; University of Michigan Head and Neck SPORE Program.

JAMA Otolaryngol Head Neck Surg. 2019 Sep 5. doi: 10.1001/jamaoto.2019.2427. [Epub ahead of print]

PMID:
31486841
4.

Pretreatment Dietary Patterns Are Associated with the Presence of Nutrition Impact Symptoms 1 Year after Diagnosis in Patients with Head and Neck Cancer.

Crowder SL, Sarma KP, Mondul AM, Chen YT, Li Z, Pepino MY, Zarins KR, Wolf GT, Rozek LS, Arthur AE.

Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1652-1659. doi: 10.1158/1055-9965.EPI-19-0128. Epub 2019 Jul 17.

PMID:
31315911
5.

Assessment of Intraoperative Nerve Monitoring Parameters Associated With Facial Nerve Outcome in Parotidectomy for Benign Disease.

Haring CT, Ellsperman SE, Edwards BM, Kileny P, Kovatch D, Mannarelli GR, Meloch MA, Miller C, Pitts C, Prince MEP, Bradford CR, Wolf GT, Casper KA, Malloy KM, Chinn SB, Shuman AG, McKean EL, VanKoevering KK, Stucken CL, McLean SA, Marentette LJ, Rosko AJ, Spector ME.

JAMA Otolaryngol Head Neck Surg. 2019 May 2. doi: 10.1001/jamaoto.2019.1041. [Epub ahead of print]

PMID:
31045218
6.

Soy Isoflavone Supplementation Increases Long Interspersed Nucleotide Element-1 (LINE-1) Methylation in Head and Neck Squamous Cell Carcinoma.

Rozek LS, Virani S, Bellile EL, Taylor JMG, Sartor MA, Zarins KR, Virani A, Cote C, Worden FP, Mark MEP, McLean SA, Duffy SA, Yoo GH, Saba NF, Shin DM, Kucuk O, Wolf GT.

Nutr Cancer. 2019;71(5):772-780. doi: 10.1080/01635581.2019.1577981. Epub 2019 Mar 12.

PMID:
30862188
7.

Elective Paratracheal Lymph Node Dissection in Salvage Laryngectomy.

Farlow JL, Birkeland AC, Rosko AJ, VanKoevering K, Haring CT, Smith JD, Brenner JC, Shuman AG, Chinn SB, Stucken CL, Malloy KM, Moyer JS, Casper KA, McLean SA, Prince MEP, Bradford CR, Wolf GT, Chepeha DB, Spector ME.

Ann Surg Oncol. 2019 Aug;26(8):2542-2548. doi: 10.1245/s10434-019-07270-6. Epub 2019 Mar 4.

PMID:
30830535
8.

Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirus-associated oropharyngeal squamous cell carcinoma.

Hawkins PG, Mierzwa ML, Bellile E, Jackson WC, Malloy KM, Chinn SB, Spector ME, Shuman AG, Stucken CL, McLean SA, Bradford CR, Prince ME, Carey TE, Worden FP, Swiecicki PL, Taylor JMG, Wolf GT, Eisbruch A, Casper KA.

Head Neck. 2019 Apr;41(4):857-864. doi: 10.1002/hed.25336. Epub 2019 Feb 18.

PMID:
30775826
9.

Mutational profiles of persistent/recurrent laryngeal squamous cell carcinoma.

Smith JD, Birkeland AC, Rosko AJ, Hoesli RC, Foltin SK, Swiecicki P, Mierzwa M, Chinn SB, Shuman AG, Malloy KM, Casper KA, McLean SA, Wolf GT, Bradford CR, Prince ME, Brenner JC, Spector ME.

Head Neck. 2019 Feb;41(2):423-428. doi: 10.1002/hed.25444. Epub 2018 Dec 12.

PMID:
30548484
10.

Histologic pattern of invasion and epithelial-mesenchymal phenotype predict prognosis in squamous carcinoma of the head and neck.

Wolf GT, Winter W, Bellile E, Nguyen A, Donnelly CR, McHugh JB, Thomas D, Amlani L, Rozek L, Lei YL; Head and Neck SPORE Program.

Oral Oncol. 2018 Dec;87:29-35. doi: 10.1016/j.oraloncology.2018.10.010. Epub 2018 Oct 22.

PMID:
30527240
11.

Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma.

Mann JE, Smith JD, Birkeland AC, Bellile E, Swiecicki P, Mierzwa M, Chinn SB, Shuman AG, Malloy KM, Casper KA, McLean SA, Moyer JS, Wolf GT, Bradford CR, Prince ME, Carey TE, McHugh JB, Spector ME, Brenner JC.

Cancer Immunol Immunother. 2019 Feb;68(2):213-220. doi: 10.1007/s00262-018-2256-3. Epub 2018 Oct 25.

PMID:
30361882
12.

Individualized survival prediction for patients with oropharyngeal cancer in the human papillomavirus era.

Beesley LJ, Hawkins PG, Amlani LM, Bellile EL, Casper KA, Chinn SB, Eisbruch A, Mierzwa ML, Spector ME, Wolf GT, Shuman AG, Taylor JMG.

Cancer. 2019 Jan 1;125(1):68-78. doi: 10.1002/cncr.31739. Epub 2018 Oct 6.

PMID:
30291798
13.

Expressed HNSCC variants by HPV-status in a well-characterized Michigan cohort.

Qin T, Zhang Y, Zarins KR, Jones TR, Virani S, Peterson LA, McHugh JB, Chepeha D, Wolf GT, Rozek LS, Sartor MA.

Sci Rep. 2018 Jul 30;8(1):11458. doi: 10.1038/s41598-018-29599-w.

14.

IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers.

Wolf GT, Moyer JS, Kaplan MJ, Newman JG, Egan JE, Berinstein NL, Whiteside TL.

Onco Targets Ther. 2018 Jun 28;11:3731-3746. doi: 10.2147/OTT.S165411. eCollection 2018. Review.

15.

Redefining Perineural Invasion: Integration of Biology With Clinical Outcome.

Schmitd LB, Beesley LJ, Russo N, Bellile EL, Inglehart RC, Liu M, Romanowicz G, Wolf GT, Taylor JMG, D'Silva NJ.

Neoplasia. 2018 Jul;20(7):657-667. doi: 10.1016/j.neo.2018.04.005. Epub 2018 May 23.

16.

Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine.

Tan YS, Sansanaphongpricha K, Xie Y, Donnelly CR, Luo X, Heath BR, Zhao X, Bellile E, Hu H, Chen H, Polverini PJ, Chen Q, Young S, Carey TE, Nör JE, Ferris RL, Wolf GT, Sun D, Lei YL.

Clin Cancer Res. 2018 Sep 1;24(17):4242-4255. doi: 10.1158/1078-0432.CCR-17-2807. Epub 2018 May 16.

17.

Vitamin D intake and survival and recurrence in head and neck cancer patients.

Yokosawa EB, Arthur AE, Rentschler KM, Wolf GT, Rozek LS, Mondul AM.

Laryngoscope. 2018 Nov;128(11):E371-E376. doi: 10.1002/lary.27256. Epub 2018 May 14.

PMID:
29756240
18.

Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen.

Berinstein NL, McNamara M, Nguyen A, Egan J, Wolf GT.

Oncoimmunology. 2018 Feb 21;7(5):e1423173. doi: 10.1080/2162402X.2017.1423173. eCollection 2018.

19.

Retraction notice to: Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents.

Ali S, Varghese L, Pereira L, Tulunay-Ugur OE, Kucuk O, Carey TE, Wolf GT, Sarkar FH.

Cancer Lett. 2018 Jun 1;423:154. doi: 10.1016/j.canlet.2018.03.018.

20.

Higher carbohydrate intake is associated with increased risk of all-cause and disease-specific mortality in head and neck cancer patients: results from a prospective cohort study.

Arthur AE, Goss AM, Demark-Wahnefried W, Mondul AM, Fontaine KR, Chen YT, Carroll WR, Spencer SA, Rogers LQ, Rozek LS, Wolf GT, Gower BA; University of Michigan Head and Neck SPORE Program.

Int J Cancer. 2018 Sep 1;143(5):1105-1113. doi: 10.1002/ijc.31413. Epub 2018 Apr 17.

21.

Reply to L. Licitra et al.

Forastiere AA, Fisher SG, Wolf GT.

J Clin Oncol. 2018 May 1;36(13):1377-1378. doi: 10.1200/JCO.2018.77.8316. Epub 2018 Mar 20. No abstract available.

PMID:
29558279
22.

Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.

Tan YS, Sansanaphongpricha K, Prince MEP, Sun D, Wolf GT, Lei YL.

J Dent Res. 2018 Jun;97(6):627-634. doi: 10.1177/0022034518764416. Epub 2018 Mar 13. Review.

23.

Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma.

Hoesli R, Birkeland AC, Rosko AJ, Issa M, Chow KL, Michmerhuizen NL, Mann JE, Chinn SB, Shuman AG, Prince ME, Wolf GT, Bradford CR, McHugh JB, Brenner JC, Spector ME.

Oral Oncol. 2018 Feb;77:83-89. doi: 10.1016/j.oraloncology.2017.12.003. Epub 2017 Dec 23.

24.

Head and neck paragangliomas: A two-decade institutional experience and algorithm for management.

Smith JD, Harvey RN, Darr OA, Prince ME, Bradford CR, Wolf GT, Else T, Basura GJ.

Laryngoscope Investig Otolaryngol. 2017 Nov 11;2(6):380-389. doi: 10.1002/lio2.122. eCollection 2017 Dec.

25.

Hypothyroidism and Wound Healing After Salvage Laryngectomy.

Rosko AJ, Birkeland AC, Bellile E, Kovatch KJ, Miller AL, Jaffe CC, Shuman AG, Chinn SB, Stucken CL, Malloy KM, Moyer JS, Casper KA, Prince MEP, Bradford CR, Wolf GT, Chepeha DB, Spector ME.

Ann Surg Oncol. 2018 May;25(5):1288-1295. doi: 10.1245/s10434-017-6278-4. Epub 2017 Dec 20.

26.

Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

Forastiere AA, Ismaila N, Wolf GT.

J Oncol Pract. 2018 Feb;14(2):123-128. doi: 10.1200/JOP.2017.027912. Epub 2017 Nov 27. No abstract available.

PMID:
29172913
27.

Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Forastiere AA, Ismaila N, Lewin JS, Nathan CA, Adelstein DJ, Eisbruch A, Fass G, Fisher SG, Laurie SA, Le QT, O'Malley B, Mendenhall WM, Patel S, Pfister DG, Provenzano AF, Weber R, Weinstein GS, Wolf GT.

J Clin Oncol. 2018 Apr 10;36(11):1143-1169. doi: 10.1200/JCO.2017.75.7385. Epub 2017 Nov 27.

PMID:
29172863
28.

Individualized outcome prognostication for patients with laryngeal cancer.

Hoban CW, Beesley LJ, Bellile EL, Sun Y, Spector ME, Wolf GT, Taylor JMG, Shuman AG.

Cancer. 2018 Feb 15;124(4):706-716. doi: 10.1002/cncr.31087. Epub 2017 Nov 7.

29.

Predictors of survival after total laryngectomy for recurrent/persistent laryngeal squamous cell carcinoma.

Birkeland AC, Beesley L, Bellile E, Rosko AJ, Hoesli R, Chinn SB, Shuman AG, Prince ME, Wolf GT, Bradford CR, Brenner JC, Spector ME.

Head Neck. 2017 Dec;39(12):2512-2518. doi: 10.1002/hed.24918. Epub 2017 Sep 30.

30.

Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma.

Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, Wolf GT, Walline HM, Bellile E, Riddell J 4th, Pai SI, Sidransky D, Westra WH, William WN Jr, Lee JJ, El-Naggar AK, Ferris RL, Seethala R, Grandis JR, Chen ZG, Saba NF, Shin DM; Head and Neck Cancer SPORE HIV supplement consortium.

Head Neck. 2017 Dec;39(12):2433-2443. doi: 10.1002/hed.24911. Epub 2017 Sep 25.

31.

HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers.

Koneva LA, Zhang Y, Virani S, Hall PB, McHugh JB, Chepeha DB, Wolf GT, Carey TE, Rozek LS, Sartor MA.

Mol Cancer Res. 2018 Jan;16(1):90-102. doi: 10.1158/1541-7786.MCR-17-0153. Epub 2017 Sep 19.

32.

Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond.

de Bree R, Wolf GT, de Keizer B, Nixon IJ, Hartl DM, Forastiere AA, Haigentz M Jr, Rinaldo A, Rodrigo JP, Saba NF, Suárez C, Vermorken JB, Ferlito A.

Head Neck. 2017 Nov;39(11):2329-2349. doi: 10.1002/hed.24883. Epub 2017 Aug 17. Review.

33.

Capecitabine after Surgical Salvage in Recurrent Squamous Cell Carcinoma of Head and Neck.

Manohar PM, Sapir E, Bellile E, Swiecicki PL, Pearson AT, Prince ME, Shuman AG, Bradford CR, Chepeha DB, Wolf GT, Eisbruch A, Worden FP, Spector ME.

Otolaryngol Head Neck Surg. 2017 Dec;157(6):995-997. doi: 10.1177/0194599817722948. Epub 2017 Aug 15.

PMID:
28809131
34.

Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx.

Gainor DL, Marchiano E, Bellile E, Spector ME, Taylor JMG, Wolf GT, Hogikyan ND, Prince ME, Bradford CR, Eisbruch A, Worden F, Shuman AG.

Otolaryngol Head Neck Surg. 2017 Oct;157(4):625-630. doi: 10.1177/0194599817711374. Epub 2017 Jun 13.

35.

Preoperative Tracheostomy Is Associated with Poor Disease-Free Survival in Recurrent Laryngeal Cancer.

Birkeland AC, Rosko AJ, Beesley L, Bellile E, Chinn SB, Shuman AG, Prince ME, Wolf GT, Bradford CR, Brenner JC, Spector ME.

Otolaryngol Head Neck Surg. 2017 Sep;157(3):432-438. doi: 10.1177/0194599817709236. Epub 2017 Jun 6.

36.

Family history of cancer and head and neck cancer survival.

Getz KR, Rozek LS, Peterson LA, Bellile EL, Taylor JMG, Wolf GT, Mondul AM.

Laryngoscope. 2017 Aug;127(8):1816-1820. doi: 10.1002/lary.26524. Epub 2017 Mar 7.

37.

Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer.

Wolf GT, Bellile E, Eisbruch A, Urba S, Bradford CR, Peterson L, Prince ME, Teknos TN, Chepeha DB, Hogikyan ND, McLean SA, Moyer J, Taylor JMG, Worden FP.

JAMA Otolaryngol Head Neck Surg. 2017 Apr 1;143(4):355-366. doi: 10.1001/jamaoto.2016.3669.

38.

Individualized risk prediction of outcomes for oral cavity cancer patients.

Prince V, Bellile EL, Sun Y, Wolf GT, Hoban CW, Shuman AG, Taylor JM.

Oral Oncol. 2016 Dec;63:66-73. doi: 10.1016/j.oraloncology.2016.11.005. Epub 2016 Nov 23.

39.

E6 and E7 Antibody Levels Are Potential Biomarkers of Recurrence in Patients with Advanced-Stage Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma.

Spector ME, Sacco AG, Bellile E, Taylor JMG, Jones T, Sun K, Brown WC, Birkeland AC, Bradford CR, Wolf GT, Prince ME, Moyer JS, Malloy K, Swiecicki P, Eisbruch A, McHugh JB, Chepeha DB, Rozek L, Worden FP.

Clin Cancer Res. 2017 Jun 1;23(11):2723-2729. doi: 10.1158/1078-0432.CCR-16-1617. Epub 2016 Nov 21.

40.

Does Quitting Smoking Make a Difference Among Newly Diagnosed Head and Neck Cancer Patients?

Choi SH, Terrell JE, Bradford CR, Ghanem T, Spector ME, Wolf GT, Lipkus IM, Duffy SA.

Nicotine Tob Res. 2016 Dec;18(12):2216-2224. Epub 2016 Aug 18.

41.

Cytokines in saliva increase in head and neck cancer patients after treatment.

Russo N, Bellile E, Murdoch-Kinch CA, Liu M, Eisbruch A, Wolf GT, D'Silva NJ.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Oct;122(4):483-490.e1. doi: 10.1016/j.oooo.2016.05.020. Epub 2016 Jun 9.

42.

Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer.

Lei Y, Xie Y, Tan YS, Prince ME, Moyer JS, Nör J, Wolf GT.

Oral Oncol. 2016 Oct;61:159-65. doi: 10.1016/j.oraloncology.2016.08.003. Epub 2016 Aug 21. Review.

43.

Multiple imputation of missing covariates for the Cox proportional hazards cure model.

Beesley LJ, Bartlett JW, Wolf GT, Taylor JM.

Stat Med. 2016 Nov 20;35(26):4701-4717. doi: 10.1002/sim.7048. Epub 2016 Jul 21.

44.

Cigarette use, comorbidities, and prognosis in a prospective head and neck squamous cell carcinoma population.

Peterson LA, Bellile EL, Wolf GT, Virani S, Shuman AG, Taylor JM, Rozek LS; University of Michigan Head and Neck Specialized Program of Research Excellence Program.

Head Neck. 2016 Dec;38(12):1810-1820. doi: 10.1002/hed.24515. Epub 2016 Jul 19.

45.

Genomic Integration of High-Risk HPV Alters Gene Expression in Oropharyngeal Squamous Cell Carcinoma.

Walline HM, Komarck CM, McHugh JB, Bellile EL, Brenner JC, Prince ME, McKean EL, Chepeha DB, Wolf GT, Worden FP, Bradford CR, Carey TE.

Mol Cancer Res. 2016 Oct;14(10):941-952. Epub 2016 Jul 15.

46.

Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials.

Sanabria A, Chaves ALF, Kowalski LP, Wolf GT, Saba NF, Forastiere AA, Beitler JJ, Nibu KI, Bradford CR, Suárez C, Rodrigo JP, Strojan P, Rinaldo A, de Bree R, Haigentz M Jr, Takes RP, Ferlito A.

Auris Nasus Larynx. 2017 Feb;44(1):18-25. doi: 10.1016/j.anl.2016.06.005. Epub 2016 Jul 5. Review.

PMID:
27397024
47.

Classification of TP53 mutations and HPV predict survival in advanced larynx cancer.

Scheel A, Bellile E, McHugh JB, Walline HM, Prince ME, Urba S, Wolf GT, Eisbruch A, Worden F, Carey TE, Bradford C.

Laryngoscope. 2016 Sep;126(9):E292-9. doi: 10.1002/lary.25915. Epub 2016 Jun 27.

48.

A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.

Swiecicki PL, Bellile E, Sacco AG, Pearson AT, Taylor JM, Jackson TL, Chepeha DB, Spector ME, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Sukari A, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey TE, Wang S, Nör JE, Worden FP.

Invest New Drugs. 2016 Aug;34(4):481-9. doi: 10.1007/s10637-016-0364-5. Epub 2016 May 26.

49.

Subtypes of HPV-Positive Head and Neck Cancers Are Associated with HPV Characteristics, Copy Number Alterations, PIK3CA Mutation, and Pathway Signatures.

Zhang Y, Koneva LA, Virani S, Arthur AE, Virani A, Hall PB, Warden CD, Carey TE, Chepeha DB, Prince ME, McHugh JB, Wolf GT, Rozek LS, Sartor MA.

Clin Cancer Res. 2016 Sep 15;22(18):4735-45. doi: 10.1158/1078-0432.CCR-16-0323. Epub 2016 Apr 18.

50.

Socioeconomic and Other Demographic Disparities Predicting Survival among Head and Neck Cancer Patients.

Choi SH, Terrell JE, Fowler KE, McLean SA, Ghanem T, Wolf GT, Bradford CR, Taylor J, Duffy SA.

PLoS One. 2016 Mar 1;11(3):e0149886. doi: 10.1371/journal.pone.0149886. eCollection 2016.

Supplemental Content

Support Center